BNT166a
Phase 1/2Active 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Monkeypox
Conditions
Monkeypox
Trial Timeline
Sep 21, 2023 → Mar 1, 2026
NCT ID
NCT05988203About BNT166a
BNT166a is a phase 1/2 stage product being developed by BioNTech for Monkeypox. The current trial status is active. This product is registered under clinical trial identifier NCT05988203. Target conditions include Monkeypox.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07379580 | Phase 2 | Recruiting |
| NCT05988203 | Phase 1/2 | Active |
Competing Products
5 competing products in Monkeypox
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BNT166a | BioNTech | Phase 2 | 49 |
| MVA-BN | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 74 |
| JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation) | Bavarian Nordic | Phase 3 | 74 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 49 |